Synthetic AAV Enhancer-Promoter for Large CFTR Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing recombinant adeno-associated virus (rAAV) vectors face limitations in efficiently expressing large transgenes due to packaging constraints and inefficient post-entry processing, particularly in airway epithelial cells, which hampers cystic fibrosis gene therapy and other gene therapy applications.

Innovation Solution

Employing a combination of a synthetic enhancer and promoter, such as the F5tg83 enhancer/promoter, to enhance transgene expression in rAAV vectors, allowing for the delivery of large genes like CFTR by augmenting transcriptional activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If rAAV vectors are used to deliver large transgenes like CFTR, then gene therapy potential is improved, but packaging capacity and transcriptional efficiency are insufficient

Engineering Contradiction:

Improvetransgene expression efficiencyVSAvoidpackaging capacity

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent changes the parameters of the promoter and enhancer sequences to optimize transcriptional efficiency. Specifically, it uses a synthetic promoter (tg83) with specific transcription factor binding sites and combines it with synthetic enhancer elements (F5, F10) to achieve high-level expression of large transgenes within the constrained rAAV packaging capacity.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite regulatory element by combining the synthetic promoter tg83 with synthetic enhancer sequences (F5, F10) to form an integrated transcriptional control module. This composite structure synergistically enhances transcriptional efficiency, enabling robust expression of large transgenes like CFTR within the limited rAAV genome capacity.

Inventive Principle:

Principle #40Composite materials

2Reliability

If the transgene size is increased to include full-length CFTR, then therapeutic efficacy is improved, but vector genome size exceeds optimal packaging limits

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidvector genome size

Core Design Contradiction:

ReliabilityVSLength of stationary object

Solution Approach 1:

The patent extracts and optimizes only the essential regulatory elements (promoter and enhancer) needed for high-level transcriptional activity, rather than using larger native promoters. This allows the full-length CFTR transgene to be packaged within the rAAV capacity limit by minimizing the regulatory sequence footprint while maximizing transcriptional efficiency.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the parameters of regulatory sequences by designing synthetic promoters and enhancers with optimized transcription factor binding sites and spacing, achieving high transcriptional efficiency with compact sequences that fit within the constrained rAAV genome capacity while supporting full-length CFTR expression.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If synthetic enhancers are added to increase transcriptional activity, then transgene expression is improved, but vector complexity increases

Engineering Contradiction:

Improvetranscriptional activityVSAvoidvector complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent segments the transcriptional control function into distinct modular elements: a synthetic promoter (tg83) containing specific transcription factor binding sites, and separate synthetic enhancer elements (F5, F10). This segmentation allows for systematic optimization of each element's contribution to transcriptional efficiency while maintaining manageable vector design and assembly.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20250381308A1AAV-mediated expression using a synthetic promoter and enhancer

Publication Date: 2025.12.18 THE UNIVERSITY OF IOWA RESEARCH

AI summary

An isolated recombinant parvovirus vector comprising a synthetic enhancer comprising plurality of enhancer sequences operably linked to a promoter, and methods of using the vector, are provided.